Karel Allegaert is a pediatrician (1999), a neonatologist (2000), and clinical pharmacologist (2003), and is currently appointed at KU Leuven, departments of Development and Regeneration, and Pharmaceutical and Pharmacological Sciences as full professor, with an additional appointment as senior consultant (10%) at Erasmus MC, Rotterdam (Hospital Pharmacy). His research focuses on perinatal and pediatric clinical pharmacology and its co-variates (maturational, non-maturational, pharmacogenetics, disease-related), with the subsequent use of in vivo datasets to develop prediction models. In a truly international and interdisciplinary connection and collaboration, this resulted in a rather extended scientific output (658 PubMed papers, H index 55, publications 770, 13 500 citations (https://www.webofscience.com/wos/author/record/C-3611-2016), and about 50 textbook chapters. The most relevant science categories are pediatrics, pharmacology and pharmacy, medicine research, microbiology and microbiology, toxicology, and lactation-related drug exposure. Links to retrieve the scientific output are accessible in the public domain: https://www.researchgate.net/profile/Karel-Allegaert. The commitment to creating societal impact is reflected in advisory tasks within the field of pharmacology and medicine, like membership of the Commission on Human Medicines, council member to the Royal Academy of Medicine Belgium (since 2015), and member trial board, KCE Belgium. He is also a member of the HCP-WP and the expert screening panel on medical devices of the European Medicines Agency. He is highly involved in different pediatric formularies (kinderformularium, Australasian neonatal formulary, MADAM).